Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel medicine eluting supporting stand

A technology for eluting stents and drugs, used in stents, medical science, surgery, etc., can solve problems such as unexplainable, achieve the effect of reducing burden, good clinical and commercial prospects, and reducing the risk of acute myocardial infarction or death

Inactive Publication Date: 2007-12-05
刘毅然 +1
View PDF0 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The study confirmed that ginkgolide B, ginkgolide A, and a mixture of ginkgolide B inhibited the proliferation of VSMCs in a concentration-dependent manner, whether induced by angiotensin II or not, and the mechanism could not be explained by PAF inhibition alone

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel medicine eluting supporting stand
  • Novel medicine eluting supporting stand
  • Novel medicine eluting supporting stand

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Weigh an appropriate amount of ginkgolide B and polylactic acid, the weight percentage of which is 3:7, and ultrasonically dissolve them with tetrahydrofuran to obtain a coating solution with a weight percentage of 1%. The prepared coating solution is atomized and sprayed onto the surface of the pretreated bare metal stent. The stent was then dried at 60° C. and a vacuum of 0.1 Mpa to prepare a ginkgolide B coating. Weigh an appropriate amount of polylactic acid, and ultrasonically dissolve it with tetrahydrofuran to obtain a coating solution with a weight percentage of 0.5%. The polylactic acid coating liquid is coated on the surface of the drug stent coated with the ginkgolide B coating by the aforementioned coating method to obtain the ginkgolide B eluting stent.

Embodiment 2

[0036] Weigh an appropriate amount of rapamycin and polymethyl methacrylate nano-silicon dioxide composite material, the weight percentage of the two is 3:7, and ultrasonically dissolve it with tetrahydrofuran to obtain a coating solution with a weight percentage of 1%. The prepared coating solution is atomized and sprayed onto the surface of the pretreated bare metal stent. Then the stent was dried at 60° C. and a vacuum of 0.1 Mpa to prepare a rapamycin coating. Weigh an appropriate amount of ginkgolide B and polymethyl methacrylate nano-silicon dioxide composite material, the weight percentage of the two is 2:8, and ultrasonically dissolve with dichloromethane to obtain a coating solution with a weight percentage of 1%. The ginkgolide B coating liquid is coated on the surface of the rapamycin-coated drug stent by using the aforementioned coating method to obtain a rapamycin-gingkolide B composite eluting stent.

Embodiment 3

[0038] Weigh an appropriate amount of paclitaxel and poly-L-lactic acid (PLLA) with a weight percentage of 4:6, and ultrasonically dissolve them with tetrahydrofuran to obtain a coating solution with a weight percentage of 1%. The prepared coating solution is atomized and sprayed onto the surface of the pretreated bare metal stent. Then the stent was dried at 60° C. and a vacuum of 0.1 Mpa to prepare paclitaxel coating. Weigh an appropriate amount of ginkgolide B and PLLA, the weight percentage of which is 2:8, and ultrasonically dissolve them with tetrahydrofuran to obtain a coating solution with a weight percentage of 1%. Apply the coating solution of ginkgolide B to the surface of the paclitaxel-coated drug stent by using the aforementioned coating method to obtain a paclitaxel-ginkgolide B composite eluting stent.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The medicated cardiovascular rack carries active component containing ginkgo terpene lactone. After being implanted inside in vivo lumen, the medicated cardiovascular rack can release ginkgo terpene lactone continuously to inhibit the proliferation of smooth muscle cell and the extracellular matrix synthesis. The medicated cardiovascular rack has also functions of promoting endothelium formation, antagonizing thrombosis, antagonizing oxidation, resisting inflammation, etc.

Description

technical field [0001] The invention relates to a new drug-eluting stent, which belongs to the scope of medical equipment. Background technique [0002] Percutaneous coronary intervention (PCI) is one of the main methods for the treatment of coronary heart disease at present. The postoperative stenosis seriously limits the long-term effect, which is the main problem that plagues the interventional treatment of coronary heart disease. Half a year after intervention, the restenosis rate of PTCA is 30% to 50%, and that of simple stenting is 15% to 30%. The mechanism of restenosis mainly includes vascular elastic contraction, thrombosis, neointimal hyperplasia and vascular remodeling. Intracoronary stents supplemented with effective new antiplatelet drugs have largely solved the problems of elastic recoil, vascular remodeling and thrombus, but neointimal hyperplasia has become the main cause of in-stent restenosis. In order to prevent the occurrence of in-stent restenosis (In-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61L31/16A61L31/12A61F2/82A61K31/365
Inventor 刘毅然许才德
Owner 刘毅然
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com